Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Chemo Neoadjuvant for TNBC (KEYNOTE-173)
NCT02622074Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2016
- Primary completion
- May 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of pembrolizumab in triple-negative breast cancer (TNBC) (6 cohorts), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicities, Adverse Events up to 28 months and 1 more. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02622074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02622074.